Analysis of Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines - aVenture Research
BioSpace
Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines
NEW YORK & BOSTON--(BUSINESS WIRE)--#AI--Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, today announced an oversubscribed $80M seed financing. The round was led by DCVC, with participation from NVentures (NVIDIA’s venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures, and additional strategic and institutional investors.
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.